Nanotechnology-Driven Strategy Against SARS-CoV-2: Pluronic F127-Based Nanomicelles with or Without Atazanavir Reduce Viral Replication in Calu-3 Cells DOI Creative Commons
Eduardo Ricci‐Júnior, Alice dos Santos Rosa, Tatielle do Nascimento

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(4), P. 518 - 518

Published: April 1, 2025

Despite extensive efforts, no highly effective antiviral molecule exists for treating moderate and severe COVID-19. Nanotechnology has emerged as a promising approach developing novel drug delivery systems to enhance efficacy. Among these, polymeric nanomicelles improve the solubility, bioavailability, cellular uptake of therapeutic agents. In this study, Pluronic F127-based were developed evaluated their activity against SARS-CoV-2. The nanomicelles, formulated using direct dissolution method, exhibited an average size 37.4 ± 8.01 nm polydispersity index (PDI) 0.427 0.01. Their efficacy was assessed in SARS-CoV-2-infected Vero E6 Calu-3 cell models, where treatment with 1:2 dilution inhibited viral replication by more than 90%. Cytotoxicity assays confirmed non-toxic both lines after 72 h. cells (human type II pneumocyte model), containing atazanavir (ATV) significantly reduced replication, even under high MOI (2) 48 h, while also preventing IL-6 upregulation. To investigate mechanism, pretreatment showed inhibitory effect. However, pre-exposure led significant reduction (>85% >75% 1:4 dilutions, respectively), transmission electron microscopy. These findings highlight nanotechnology-driven strategy SARS-CoV-2, reinforcing potential future therapies.

Language: Английский

Biophysics of SARS-CoV-2 spike protein’s receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights DOI
Fernando Luís Barroso da Silva,

Karen Paco,

Aatto Laaksonen

et al.

Biophysical Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Language: Английский

Citations

1
Nanotechnology-Driven Strategy Against SARS-CoV-2: Pluronic F127-Based Nanomicelles with or Without Atazanavir Reduce Viral Replication in Calu-3 Cells DOI Creative Commons
Eduardo Ricci‐Júnior, Alice dos Santos Rosa, Tatielle do Nascimento

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(4), P. 518 - 518

Published: April 1, 2025

Despite extensive efforts, no highly effective antiviral molecule exists for treating moderate and severe COVID-19. Nanotechnology has emerged as a promising approach developing novel drug delivery systems to enhance efficacy. Among these, polymeric nanomicelles improve the solubility, bioavailability, cellular uptake of therapeutic agents. In this study, Pluronic F127-based were developed evaluated their activity against SARS-CoV-2. The nanomicelles, formulated using direct dissolution method, exhibited an average size 37.4 ± 8.01 nm polydispersity index (PDI) 0.427 0.01. Their efficacy was assessed in SARS-CoV-2-infected Vero E6 Calu-3 cell models, where treatment with 1:2 dilution inhibited viral replication by more than 90%. Cytotoxicity assays confirmed non-toxic both lines after 72 h. cells (human type II pneumocyte model), containing atazanavir (ATV) significantly reduced replication, even under high MOI (2) 48 h, while also preventing IL-6 upregulation. To investigate mechanism, pretreatment showed inhibitory effect. However, pre-exposure led significant reduction (>85% >75% 1:4 dilutions, respectively), transmission electron microscopy. These findings highlight nanotechnology-driven strategy SARS-CoV-2, reinforcing potential future therapies.

Language: Английский

Citations

0